Eli Lilly (LLY) Other Non-Current Liabilities (2009 - 2026)

Eli Lilly has reported Other Non-Current Liabilities for 18 years, with the latest figure at $4.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 78.51% year-over-year to $4.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (up 78.51% YoY), and the FY2025 full-year result was $4.0 billion, down 2.24% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.1 billion, up from $4.0 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $6.3 billion in Q3 2025, with the low at $1.7 billion in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $2.8 billion across 5 years, with a median of $2.3 billion in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 52.3% — and 2025, when it surged 181.04%.
• Eli Lilly's Other Non-Current Liabilities stood at $1.8 billion in 2022, then increased by 22.84% to $2.2 billion in 2023, then soared by 81.25% to $4.1 billion in 2024, then fell by 2.24% to $4.0 billion in 2025, then gained by 2.9% to $4.1 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.1 billion (Q1 2026), $4.0 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.